Key facts
- It has raised $1.1M; the latest was Seed Round ($1.1M) in Oct 2025.
- Notable investors include Genesis Pre-Seed Fund, The University of Melbourne.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for PredicTx Health
- ·The full record, as it builds
Funding rounds
No funding rounds for PredicTx Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PredicTx Health
Operator of an AI-powered precision cancer chemotherapy dosing service intended to personalize oncology treatment, reduce toxicity and improve patient outcomes. The company offers accurate and personalized cancer care through AI-powered precision dosing, utilizing CT-based body composition, enabling customers to deliver world-class, patient-tailored chemotherapy treatments and achieve improved patient outcomes with reduced toxicity.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2025
- Employees
- 10
- Website
- predictx.health/
- Ownership
- Privately Held (backing)
PredicTx Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PredicTx Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PredicTx Health in its N-PORT filings yet. We sweep new filings monthly.